[go: up one dir, main page]

AR020084A1 - Pestivirus atenuados - Google Patents

Pestivirus atenuados

Info

Publication number
AR020084A1
AR020084A1 ARP990102650A ARP990102650A AR020084A1 AR 020084 A1 AR020084 A1 AR 020084A1 AR P990102650 A ARP990102650 A AR P990102650A AR P990102650 A ARP990102650 A AR P990102650A AR 020084 A1 AR020084 A1 AR 020084A1
Authority
AR
Argentina
Prior art keywords
pestivirus
glycoprotein
vaccine
pestiviruses
residing
Prior art date
Application number
ARP990102650A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR020084A1 publication Critical patent/AR020084A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pestivirus específicamente atenuados y marcados en forma detectable para uso como vacunas atenuadas vivas con una elevada con una elevada eficacia para lainduccion de inmunidad que también se pueden distinguir de pestivirus patogenos procedentes delcampo. Una vacuna viva que comprende un pestivirus, en la quela actividad de RNasa que reside en la glicoproteina E(RNS) está inactivada. Un pestivirus para una vacuna, en el que la actividad de RNasa que reside en laglicoproteína E(RNS) estáinactiv ada por deleciones y/o mutaciones de al menos un aminoácido de dicha glicoproteína, con la condicion de que los aminoácidos enla posicion 297 y/o 346 de dicha proteína no sean lisina. Un ácido nucleico que codifica una glicoproteína que seexpresa en un pestivirus, en el que laactividad de RNasa que reside en dicha glicoproteína ERNS está inactivada por deleciones y/o mutaciones de al menos un aminoácido de dicha glicoproteína, conla condicion de que los aminoácidos en la posicion 297y/o 346 de dicha proteína no sean lisina. El empleo de ácidos nucleicos para preparar vacunas denucleotidos y/o vectores. Una composicion farmacéutica que contiene una vacuna, y/o un pestivirus, y/o una secuencia de nucleotidos. Un método paraatenuarpestiviru s destinados a la vacuna, un método para producir una vacuna específicamente atenuada, un método para marcar de forma detectable pestivirus, un métodopara la profilaxis y el tratamiento de infecciones por pestivirus, unprocedimiento para la preparac ion de pestivirus específicamente atenuados y un métodopara distinguir animales infestados por pestivirus de animales vacunados con un pestivirus específicamente atenuado. El uso de la y de la composicionfarmacéuticapara la profilaxis y el tratamien to de infecciones por pestivirus en animales. El uso de un pestivirus y/o una secuencia de nucleotidospara preparar una vacuna o una composicion farmacéutica.
ARP990102650A 1998-06-05 1999-06-04 Pestivirus atenuados AR020084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110356A EP0965639A1 (en) 1998-06-05 1998-06-05 Attenuated pestiviruses

Publications (1)

Publication Number Publication Date
AR020084A1 true AR020084A1 (es) 2002-04-10

Family

ID=8232074

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990102650A AR020084A1 (es) 1998-06-05 1999-06-04 Pestivirus atenuados
ARP090101843A AR071881A2 (es) 1998-06-05 2009-05-22 Pestivirus atenuados
ARP090101842A AR071880A2 (es) 1998-06-05 2009-05-22 Metodo para marcar de forma detectable pestivirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP090101843A AR071881A2 (es) 1998-06-05 2009-05-22 Pestivirus atenuados
ARP090101842A AR071880A2 (es) 1998-06-05 2009-05-22 Metodo para marcar de forma detectable pestivirus

Country Status (23)

Country Link
EP (5) EP0965639A1 (es)
JP (3) JP4632540B2 (es)
KR (1) KR100637940B1 (es)
CN (2) CN101085346A (es)
AR (3) AR020084A1 (es)
AT (3) ATE286131T1 (es)
AU (1) AU769823C (es)
BR (2) BRPI9917787B1 (es)
CA (1) CA2330241C (es)
CO (1) CO5050392A1 (es)
CZ (3) CZ301569B6 (es)
DE (3) DE69928700T2 (es)
DK (3) DK1203813T3 (es)
ES (3) ES2235488T3 (es)
HU (3) HU228468B1 (es)
NZ (1) NZ509228A (es)
PE (1) PE20000552A1 (es)
PL (2) PL202509B1 (es)
PT (2) PT1203813E (es)
SI (3) SI1203812T1 (es)
SK (3) SK287014B6 (es)
TR (3) TR200103666T2 (es)
WO (1) WO1999064604A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
EP1104676A1 (en) * 1999-11-30 2001-06-06 Boehringer Ingelheim Vetmedica Gmbh Safe attenuated bovine viral diarrhea viruses for use in pregnant cows
PT1149901E (pt) 2000-04-21 2006-08-31 Akzo Nobel Nv Mutantes de pestivirus e vacinas contendo os mesmos
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CL2008003202A1 (es) 2007-10-29 2009-11-27 Boehringer Ingelheim Vetmedica Inc Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
UY31930A (es) 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
WO2010051210A1 (en) 2008-10-31 2010-05-06 Boehringer Ingelheim Vetmedica, Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
US8846054B2 (en) 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
CN101915837B (zh) * 2010-07-28 2013-07-03 中国兽医药品监察所 一种猪瘟兔化弱毒活疫苗效力检验方法
ES2606605T3 (es) 2010-09-21 2017-03-24 Intervet International B.V. Vacuna para el BVDV
CN103882051B (zh) * 2014-03-20 2016-04-06 北京市农林科学院 一种检测猪瘟病毒抗体的elisa方法及检测试剂盒
US9993544B2 (en) * 2014-05-23 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Recombinant classical swine fever virus (CSFV) comprising substitution in the TAV epitope of the E2 protein
KR20220009960A (ko) * 2019-04-18 2022-01-25 베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드 재조합 고전적 돼지 열병 바이러스

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752389T2 (de) * 1986-01-27 2007-06-14 Schering-Plough Ltd. Attenuierte Herpesviren, Herpesviren die eine Aminosäuresequenz kodierende fremde DNA enthalten, und diese enthaltende Impfstoffe

Also Published As

Publication number Publication date
CN101085346A (zh) 2007-12-12
CO5050392A1 (es) 2001-06-27
DK1084251T3 (da) 2005-04-11
NZ509228A (en) 2003-12-19
WO1999064604A3 (en) 2000-01-27
ATE286131T1 (de) 2005-01-15
SK18232000A3 (sk) 2001-05-10
HU228468B1 (en) 2013-03-28
JP2002517250A (ja) 2002-06-18
EP1203813A2 (en) 2002-05-08
PL202161B1 (pl) 2009-06-30
AU4369299A (en) 1999-12-30
JP2013099357A (ja) 2013-05-23
EP0965639A1 (en) 1999-12-22
BR9911619A (pt) 2001-10-02
EP1614423A2 (en) 2006-01-11
CZ301570B6 (cs) 2010-04-21
CA2330241A1 (en) 1999-12-16
BR9911619B1 (pt) 2013-11-12
BRPI9917787B1 (pt) 2016-09-06
SI1203813T1 (sl) 2006-06-30
AU769823B2 (en) 2004-02-05
DE69929544D1 (de) 2006-04-13
PT1203813E (pt) 2006-06-30
ES2257476T3 (es) 2006-08-01
PT1084251E (pt) 2005-03-31
TR200103664T2 (tr) 2002-06-21
WO1999064604A2 (en) 1999-12-16
JP2010259445A (ja) 2010-11-18
EP1614423A3 (en) 2008-01-30
DE69922953D1 (de) 2005-02-03
KR100637940B1 (ko) 2006-10-23
SK287626B6 (sk) 2011-04-05
ES2235488T3 (es) 2005-07-01
ATE311193T1 (de) 2005-12-15
DE69922953T2 (de) 2005-05-19
AU769823C (en) 2004-11-25
HU228471B1 (en) 2013-03-28
DE69928700D1 (de) 2006-01-05
DK1203813T3 (da) 2006-05-22
CN100374563C (zh) 2008-03-12
EP1084251B1 (en) 2004-12-29
JP5755265B2 (ja) 2015-07-29
SI1203812T1 (sl) 2006-04-30
DE69929544T2 (de) 2006-07-20
AR071881A2 (es) 2010-07-21
CN1304452A (zh) 2001-07-18
TR200103666T2 (tr) 2002-03-21
CA2330241C (en) 2010-09-21
TR200003622T2 (tr) 2001-06-21
ES2253457T3 (es) 2006-06-01
HU228469B1 (en) 2013-03-28
JP5247770B2 (ja) 2013-07-24
PL202509B1 (pl) 2009-06-30
EP1203813A3 (en) 2004-02-04
EP1203812B1 (en) 2005-11-30
EP1084251A2 (en) 2001-03-21
PL348019A1 (en) 2002-05-06
DE69928700T2 (de) 2006-06-22
AR071880A2 (es) 2010-07-21
EP1203812A2 (en) 2002-05-08
SK287625B6 (sk) 2011-04-05
SK287014B6 (sk) 2009-09-07
ATE316380T1 (de) 2006-02-15
SI1084251T1 (en) 2005-08-31
HUP0102707A2 (hu) 2001-11-28
EP1203812A3 (en) 2004-02-04
CZ301569B6 (cs) 2010-04-21
EP1203813B1 (en) 2006-01-25
CZ301494B6 (cs) 2010-03-24
CZ20004533A3 (cs) 2001-07-11
JP4632540B2 (ja) 2011-02-16
HUP0102707A3 (en) 2008-04-28
PE20000552A1 (es) 2000-07-14
DK1203812T3 (da) 2006-04-10
KR20010071406A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
AR020084A1 (es) Pestivirus atenuados
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
UY26783A1 (es) Antígenos de estreptococo.
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
SI2280721T1 (en) Indoleamine 2, 3-dioxygenase based immunotherapy
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
CY1107188T1 (el) Εμβολιο ε. coli πτηνου για την προστασια εναντι κολοβακτηριωσης
WO2023094713A3 (en) Coronavirus vaccine
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
AR109538A1 (es) Vacuna contra la gripe porcina
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
RU2008102654A (ru) Инактивированные химерные вакцины и связанные с ними способы применения
BR0006291A (pt) Bactéria do gênero salmonella, vacina para aproteção de animais contra a salmonelose, uso deuma bactéria, e, processo para a preparação deuma vacina
AR123244A1 (es) Vacuna de salmonella para el tratamiento de coronavirus
DK0653489T3 (da) Coccidiosisvaccine til fjerkræ
FR2828405B1 (fr) Vaccin anti-coronavirus
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE252153T1 (de) Rekombinanter birnavirusimpfstoff
ES2063897T3 (es) Vacuna contra el virus del colera porcino y diagnostico.
WO2006046017A8 (en) Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter
DE69521007D1 (de) Impfstoff gegen Geflügelkokzidose

Legal Events

Date Code Title Description
FG Grant, registration